# Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

> **NCT06753981** · — · RECRUITING · sponsor: **Qianfoshan Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Arterial Pulmonary Hypertension (PAH)

## Interventions

- **DRUG:** Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs

## Key facts

- **NCT ID:** NCT06753981
- **Lead sponsor:** Qianfoshan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2026-11-14
- **Final completion:** 2027-02-14
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-12-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06753981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06753981, "Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06753981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*